From Molecular Design to Clinical Durability: Extending Ocular Half- Life with the Antibody Biopolymer Conjugate (ABC) Platform
9:00 am - Wednesday 20th January 2027
- Explore how the ABC Platform increases molecular size and extends ocular residence time
- Review clinical evidence linking tarcocimab’s approximately 20-day ocular halflife to durable disease control and longer dosing intervals
- Discover how the Antibody Biopolymer Conjugate Drug (ABCD) Platform extends ABC into a modular system for the tailored delivery of diverse drug cargos and durable multi-mechanism therapies
